UK drug regulator flags Goa Plant I of Indoco Remedies

Gayathri Udyawar
/ Categories: Trending, Markets

Indoco Remedies informed that the UK-MHRA has issued GMP non-compliance to the company's Plant I in Goa.

 

The drug regulator inspected the plant from March 14 to 16, 2018 and issued three critical and four major observations. This gives the plant non-compliance and restricted GMP certificate which permits the plant to continue manufacturing and testing of products that are medically critical. However, since there were no evidence of impact on product, the regulator has not recommend a recall.

 

The company has said that it is hopeful of resolving the issues with the European authorities. But in the interim there will be a temporary impact on the company's business in Europe. However, the company will minimize by the affect by transferring production to the company's other facilities in Goa III and Baddi I, Harayan which has the required regulatory clearance.

 

Meanwhile, the stock of Indoco Remedies closed at Rs. 210.00 per share, down 4.15 per cent on Wednesday.

Previous Article Mutual Fund Unlocked: Contra Funds
Next Article Bajaj Corp turns volatile amid Q4 result, price at crucial level
Rate this article:
5.0

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR